PACS Group, Inc. (PACS) Market Cap & Valuation Ratios
PACS Group, Inc. (PACS) has a market cap of $7.5B, a trailing P/E of 27.9 and a price-to-sales ratio of 1.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PACSPACS Group, Inc.Follow PACS — free
—
Price chart with a free account
- Market cap
- 7.5B
- P/E TTM
- 27.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Peers
medical care facilities · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| PACS | 7.5 | 27.9 | 1.4 | 15.9 | 6.0% | +15% | 7% | 29% |
| EHC | 12 | 20.2 | 2.4 | 9.8 | 3.4% | +9% | 19% | 19% |
| DVA | 12 | 15.1 | 1.6 | 7.7 | 13.7% | +6% | 15% | 18% |
| UHS | 11 | 7.6 | 0.9 | 5.8 | 7.4% | +10% | 11% | 13% |
| ENSG | 10 | 27.5 | 1.8 | 17.3 | 4.1% | +19% | 9% | 17% |
| CHE | 6.7 | 25.8 | 2.6 | 16.4 | 4.8% | +3% | 13% | 28% |
| CON | 5.0 | 25.3 | 2.8 | 14.1 | 5.3% | +14% | 16% | 15% |
| LFST | 4.9 | 99.7 | 3.1 | 37.4 | 3.5% | +20% | 5% | 4% |
| OPCH | 4.7 | 23.7 | 1.0 | 13.9 | 6.5% | +6% | 6% | 11% |
| NHC | 3.7 | 26.6 | 2.3 | 19.2 | 4.0% | +7% | 9% | 11% |
| ACHC | 2.9 | — | 1.5 | — | -4.6% | +4% | -28% | -20% |
| Median of these 10 | 25.3 | 2.1 | 14.1 | 4.5% | +8% | 10% | 14% |
P/E 27.9 vs. a peer median of 25.3; EV/Sales 1.4 vs. 2.1. PACS's own P/E sits at the 36th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesACHC has no P/E (earnings not positive) and is left out · hover or tap a dot for values.
PACS Group, Inc. — questions
- What is PACS Group, Inc.'s market cap?
- $7.5B.
- What is PACS Group, Inc.'s P/E ratio?
- 27.9 on trailing twelve-month earnings to 2026-06-30.
- What is PACS Group, Inc.'s price-to-sales ratio?
- 1.4.
Every figure on this page comes from PACS Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.